Opendata, web and dolomites


40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease

Total Cost €


EC-Contrib. €






 BRIGHT project word cloud

Explore the words cloud of the BRIGHT project. It provides you a very rough idea of what is the project "BRIGHT" about.

global    coloured    decades    believe    demonstration    approximately    appropriate    clearance    intervention    triggers    stroboscopic    maturation    reduce    sizeable    savings    ahead    formed    patent    prepare    route    players    light    company    improvements    serving    avoiding    optimal    brain    appear    onset    roll    prevalence    capturing    liaise    untap    core    colour    protected    protective    stepping    founding    bright    leds    vital    ad    delay    beta    later    devised    industrial    disease    alone    wavelengths    dementia    stimulate    instead    promotes    accumulation    drugs    minimizing    roadblocks    colours    variants    business    invasive    stone    33    neuro    while    full    patients    stages    cortex    members    significantly    visual    leverage    optoceutics    experiencing    fadigue    primarily    alternating    shows    flickering    human    cascade    inducing    blue    off    frequency    fusion    accentuates    neurodegenerative    white    clinical    representing    receptors    hz    alzheimer    combinations    led    market    damage    prior    amyloid    100bn    productization    strategy    pandemic    setup    de    irreversible    ing    certification    risk    flashing   

Project "BRIGHT" data sheet

The following table provides information about the project.


Organization address
address: DIPLOMVEJ 381
postcode: 2800
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OPTOCEUTICS APS DK (KONGENS LYNGBY) coordinator 50˙000.00


 Project objective

While Alzheimer’s Disease (AD) is a global pandemic, it has been estimated that a five-year delay in the disease onset could reduce the disease prevalence – and its costs – by up to 33% over the next decades, representing potential savings over €100bn in EU alone. However, there are still significant roadblocks ahead as current drugs do not untap sizeable improvements in AD patients. This is primarily due to the challenge of minimizing the impact of irreversible brain damage in later dementia stages, which accentuates the need for early intervention. However, recent evidence shows that non-invasive flashing (stroboscopic) light at the appropriate frequency (40 Hz) promotes clearance of beta-amyloid – whose accumulation is believe to be one of the key triggers to the neurodegenerative cascade leading to dementia states.

Instead of using fadigue-inducing stroboscopic flashing light (i.e. on-off), the founding members of OptoCeutics have devised a unique, patent-protected method to stimulate the human visual receptors and processing cortex through alternating white light composed of different wavelengths. The two variants of the white light are formed by different combinations of coloured LEDs. When flickering between the two LED sets, the colours fusion together and appear as one, resulting in approximately the same white colour, avoiding experiencing light flashing, but the brain is capturing the blue component flashing with 40 Hz – thus still promoting neuro-protective beta-amyloid clearance.

OptoCeutics will leverage from BRIGHT as a vital stepping stone to prepare the company’s business strategy, serving also to significantly de-risk its route-to-market by enabling to liaise with major industrial and clinical players to define both the optimal productization and maturation of Optoceutics core technology, as well as the setup for its full-scale demonstration and certification, prior market roll-out.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRIGHT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRIGHT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CathVision Cube (2019)

CathVision Cube: disruptive data-driven guidance for successful cardiac ablation therapy

Read More  

PD-Watch (2019)

Wearable technology for the selective detection and continuous monitoring of movement disorders related to Parkinson’s disease

Read More  

CoLumbo (2019)


Read More